CelLBxHealth (LSE:CLBX) has reported growing new Business from pharmaceutical customers, but its latest update also highlighted a tight cash position. In a third-quarter trading update and outlook for 2026 published on 21 October 2026, the liquid biopsy company said it expected 2026 Revenue of £1.8m, up 29% on 2025, and gave a revenue outlook of £3.0m to £4.0m for 2027. It said cash stood at £1.4m at the end of September, with a cash runway through the first quarter of 2027.

What the company does

CelLBxHealth works in liquid biopsy, using its Parsortix technology to capture circulating tumour cells (CTCs) from blood samples. These cells can be analysed to help understand a patient's cancer without a conventional tissue biopsy. The company provides services and products to pharmaceutical and biotech companies, which use the technology in Drug Development and clinical trials, as well as to academic and clinical researchers.

Latest developments

On 21 October 2026, alongside the trading update, the company announced a master services agreement with a Swiss biotech company. A week earlier, on 14 October, it announced a new statement of work with a US-based pharmaceutical company. In May 2026, it reported a master services agreement with a global pharmaceutical company and a collaboration with AdventHealth covering two studies.

Use of its technology in research has also featured in its news flow. In August 2026, the company published two announcements highlighting the use of Parsortix-captured CTCs in brain cancer detection and in assessing targets for antibody-drug conjugates, a fast-growing class of cancer treatment.

According to the Q3 update, new business won was £0.3m, about three times the prior year's level. The year-to-date cash operating loss was £4.0m, down about 60%, which points to a much lower rate of spending.

Financial picture

Cash of £1.4m at the end of September, plus an expected Research and Development tax Credit of £0.8m, gives the company a runway through the first quarter of 2027. That is a short horizon, and it suggests the company will need additional funding, a commercial Partnership or other measures in the coming months. Its first-half results, covering the period to 30 June 2026, were published on 15 July 2026, and its preliminary results for 2025 were released on 22 June 2026.

Sector and index context

CelLBxHealth (LSE:CLBX) is one of the healthcare technology companies in the FTSE AIM All Share Index. Liquid biopsy is an area of intense scientific and commercial interest, but competition is intense and commercial adoption has often been slower than expected. Many small AIM-quoted diagnostics companies have faced funding pressure as investor appetite for early-stage life sciences has weakened.

Key risks

The most immediate risk is funding. With a runway through the first quarter of 2027, the company may need to raise money, which could significantly dilute shareholders if done at a low share price. Revenue depends on winning and converting pharmaceutical contracts, which can be lumpy and subject to delays. Competition from alternative liquid biopsy technologies is another risk.

What to watch next

Investors will watch for any announcement on financing or strategic options, given the limited cash runway. Further contract wins, the conversion of agreements into revenue and progress towards the 2027 revenue outlook of £3.0m to £4.0m will also be key. Full-year results for 2026 would be the next scheduled set of figures, and they will show how far cost savings have extended the company's runway.